Clinical trial
"Twenty-five Years of Advanced RadioTherapy (ART), With Intensity Modulation, Image-guidance, and Stereotactic Radiotherapy, With Classic Fractionation, Moderate- or Ultra-hypofractionation at San Raffaele Hospital "
NCT07894900 is registered in ClinicalTrials.gov with IRCCS San Raffaele as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing
Registry record
As filed in ClinicalTrials.gov.
- Title
- "Twenty-five Years of Advanced RadioTherapy (ART), With Intensity Modulation, Image-guidance, and Stereotactic Radiotherapy, With Classic Fractionation, Moderate- or Ultra-hypofractionation at San Raffaele Hospital "
- Lead sponsor
- IRCCS San Raffaele
- Phase
- Observational
- Overall status
- Not yet recruiting
- Start date
- November 15, 2026
- Completion date
- November 15, 2031
- Enrollment
- 10,000 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
arteriovenous malformations, benign neoplasm, malignant tumor, parkinson disease, trigeminal neuralgia
Arms
As registered; 20 arms.
-
Lymph nodes
Tumor lymph nodes treated with stereotactic body radiotherapy (SBRT).
-
Adrenal lesions
Adrenal lesions treated with stereotactic body radiotherapy (SBRT).
-
Liver lesions
Primary or secondary liver lesions treated with CyberKnife and tomotherapy (advanced radiotherapy).
-
Lung lesions
Lung lesions treated with Stereotactic Body Radiotherapy
-
Lung metastasis and primary tumors
Lung lesions treated with stereotactic body radiotherapy (SBRT) versus moderate hypofractionated radiotherapy using advanced radiotherapy techniques.
+15 more arms
Primary endpoints
Registered primary outcome measures; 5 primary.
-
Local Relapse Free Survival
Local control of the disease (at the treated site)
-
Biochemical Relapse Free Survival
Biochemical control for prostate cancer
-
Obliteration rate
Obliteration rate of arteriovenous malformations
-
Improvement of clinical symptoms
BNI (Barrow National Institute) scale for trigeminal neuralgia, a 5-point grading system, from Grade I (Excellent outcome) without pain to Grade V (Poor treatment response) with trigeminal pain with no improvement despite treatment
-
Functional improvement after the treatment
TETRAS score or UPDRS for movement disorders, which includes two scales, Activities of Daily Living Scale with 12 items and a range of points from 0 to 48 and Performance scale with 9 items and a range of points from 0 to 64. Lower means less tremor on both subscales, and the two are reported separately rather than summed
Lead sponsor's other trials
IRCCS San Raffaele, most recent start first.
+519 more trials See the organization page
Similar trials
Same condition (Trigeminal Neuralgia) and phase, most recent start first.
+34 more trials See the condition page